Edema News and Research RSS Feed - Edema News and Research

Edema means swelling caused by fluid in your body's tissues. It usually occurs in the feet, ankles and legs, but it can involve your entire body.
Promising results for low-dose insulin in paediatric diabetic ketoacidosis

Promising results for low-dose insulin in paediatric diabetic ketoacidosis

Results of a randomised trial suggest that low-dose insulin may be at least as good as standard-dose insulin for the treatment of children with diabetic ketoacidosis. [More]
Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Janssen announces submission of IMBRUVICA sNDA to FDA for WM treatment

Janssen Research & Development, LLC today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA (ibrutinib) to the U.S. Food and Drug Administration by its strategic partner Pharmacyclics, Inc. [More]
Health Canada approves Lucentis (ranibizumab) for myopic CNV

Health Canada approves Lucentis (ranibizumab) for myopic CNV

Novartis Pharmaceuticals Canada Inc. announced today that Lucentis (ranibizumab), the treatment for several major causes of vision loss, has been approved by Health Canada for the treatment of visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV). [More]
New report shows liquid detergent pods can cause eye injuries to children

New report shows liquid detergent pods can cause eye injuries to children

Liquid laundry and dishwasher detergent pods are an emerging source of chemical exposure in children. When squeezed or bitten into, these pods can burst and send detergent into the mouth, nose, and eyes. [More]
Hercules Technology Growth Capital issues advance payment to Alimera Sciences

Hercules Technology Growth Capital issues advance payment to Alimera Sciences

Alimera Sciences, Inc. (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it has received a $25 million advance from Hercules Technology Growth Capital, Inc. (NYSE: HTGC) (Hercules). [More]
Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA® (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). [More]
Bausch + Lomb’s sub-micron loteprednol etabonate ophthalmic gel meets primary endpoint

Bausch + Lomb’s sub-micron loteprednol etabonate ophthalmic gel meets primary endpoint

Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), today announced that its next generation sub-micron gel formulation of loteprednol etabonate was statistically superior to placebo (vehicle gel) in eliminating inflammation and pain following cataract surgery by study day eight, the primary endpoints in the first Phase 3, multi-center, double-masked, vehicle-controlled, parallel-group study. [More]
Occlutech's Paravalvular Leak Closure Device European CE Mark approval

Occlutech's Paravalvular Leak Closure Device European CE Mark approval

Occlutech, a leading innovator of products to treat structural heart disease today announced that it has obtained a European CE Mark approval for its dedicated Paravalvular Leak Closure Device, (PLD). [More]
Heart Hospital of Austin becomes first facility in Texas to implant CardioMEMS HF System

Heart Hospital of Austin becomes first facility in Texas to implant CardioMEMS HF System

On Sept. 24, 2014 Heart Hospital of Austin became the first facility in Texas to implant a new miniaturized, wireless monitoring sensor to manage heart failure (HF). The CardioMEMS HF System is the first and only FDA-approved heart failure monitoring device that has been proven to significantly reduce hospital admissions when used by physicians to manage heart failure. [More]
Alimera announces FDA approval of ILUVIEN for treatment of diabetic macular edema

Alimera announces FDA approval of ILUVIEN for treatment of diabetic macular edema

Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the U.S. Food and Drug Administration has approved ILUVIEN for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). [More]
MIT researchers use disarmed version of anthrax toxin to deliver cancer drugs

MIT researchers use disarmed version of anthrax toxin to deliver cancer drugs

Bacillus anthracis bacteria have very efficient machinery for injecting toxic proteins into cells, leading to the potentially deadly infection known as anthrax. A team of MIT researchers has now hijacked that delivery system for a different purpose: administering cancer drugs. [More]
EYLEA Injection gets approval in Japan for treatment of myopic CNV

EYLEA Injection gets approval in Japan for treatment of myopic CNV

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has received approval from the Japanese Ministry of Health, Labour and Welfare for EYLEA (aflibercept) Injection for myopic choroidal neovascularization (myopic CNV). [More]
FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted EYLEA (aflibercept) Injection Breakthrough Therapy designation for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). [More]
New way to reduce abnormal blood vessel growth and leakage in eye

New way to reduce abnormal blood vessel growth and leakage in eye

Working with mice, a multicenter team of researchers has found a new way to reduce the abnormal blood vessel growth and leakage in the eye that accompany some eye diseases. The finding could lead to the development of new drugs for wet macular degeneration and diabetic macular edema. [More]
Researchers discover protein that may open door to new method of treating type 2 diabetes

Researchers discover protein that may open door to new method of treating type 2 diabetes

The STK25 protein contributes to cell growth. Researchers at Sahlgrenska Academy have discovered that the protein also affects metabolism, demonstrating that elevated levels accelerate the progress of diabetes in mice. [More]
iCo Therapeutics reports financial results for second quarter 2014

iCo Therapeutics reports financial results for second quarter 2014

iCo Therapeutics, today reported financial results for the six months ended June 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"). [More]
New wireless monitoring sensor helps doctors and patients manage heart failure problems

New wireless monitoring sensor helps doctors and patients manage heart failure problems

Unexpected trips to the hospital are inconvenient and worrisome for anyone, but for congestive heart failure sufferers, they can be all too frequent. [More]
Study examines ocular changes seen in astronauts to treat spaceflight-induced visual impairment

Study examines ocular changes seen in astronauts to treat spaceflight-induced visual impairment

To reduce and better treat spaceflight-induced visual impairment, University of Houston (UH) optometrists are collaborating on a NASA study that examines ocular changes seen in a number of astronauts. [More]
Research demonstrates that African Americans bear heavier burden of DME

Research demonstrates that African Americans bear heavier burden of DME

Research by Keck Medicine of USC ophthalmology scientists demonstrates that African Americans bear heavier burden of diabetic macular edema (DME), one of the leading causes of blindness in diabetic patients in the United States. [More]
KalVista begins Phase I trial of novel plasma kallikrein inhibitor for treatment of DME

KalVista begins Phase I trial of novel plasma kallikrein inhibitor for treatment of DME

KalVista Pharmaceuticals, an ophthalmology company with a focus on diabetic macular edema (DME), today announces that it has begun a Phase I, First in Human, trial of its novel plasma kallikrein inhibitor, KVD001, for the treatment of DME. [More]